Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

Aldeyra Ther­a­peu­tics’ shares tanked in pre­mar­ket trad­ing af­ter the com­pa­ny ad­mit­ted its dry eye can­di­date re­prox­alap missed the pri­ma­ry end­point in a topline Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER